Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7790348 | 0.87 | DRD2 (0.45) | DRD2DRD3CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL7791797 | 0.87 | DRD2 (0.45) | DRD2DRD3CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL7782683 | 0.85 | DRD2 (0.48) | DRD2DRD3CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL7787432 | 0.82 | ITGB3 (0.53) | DRD2DRD3CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL26706255 | 0.77 | CHKA (0.53) | DRD2DRD3CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL26706256 | 0.76 | CHKA (0.52) | DRD2DRD3CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL7788361 | 0.75 | ITGB3 (0.47) | DRD2DRD3CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL7790832 | 0.71 | ITGB3 (0.47) | ITGB3ITGA2BHRH3 | |
| SCHEMBL31706286 | 0.71 | DRD2 (0.48) | DRD2DRD3CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL11084741 | 0.70 | DRD2 (0.67) | DRD2DRD3DRD4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010009912-A1 | NEW DERIVATIVES OF PYRIDIL PIPERAZINE OR PYRIDAZINYL PIPERAZYL, PROCESS FOR PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THESE COMPOUNDS | TSAKLAKIDIS CHRISTOS (DE) | 2001-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009912-A1 | NEW DERIVATIVES OF PYRIDIL PIPERAZINE OR PYRIDAZINYL PIPERAZYL, PROCESS FOR PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THESE COMPOUNDS | CYP4B1, NR4A1, CYP3A43 | DRD2 752/4885DRD3 326/4885CYP17A1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.